Abstract: This invention provides Class III anti-arrhythmic agents of the formula: ##STR1## in which R.sup.1 is alkylsulfonamido, R.sup.2 is ethyl, R.sup.3 is hydrogen, R.sup.4 is ethyl, and n is 2 to 4, or a pharmaceutically acceptable salt thereof.

Abstract: N-Aminoalkyl(perfluoroalkanoylaminophenyl)sulfonic acid amides of the formula: ##STR1## in which R.sup.1 is perfluoroalkanoylamino of 2 to 4 carbon atoms, in 3- or 4- position of the benzene ring;R.sup.2 is hydrogen or alkyl of 1 to 4 carbon atoms;R.sup.3 is hydrogen or straight or branched chain alkyl of 1 to 4 carbon atoms;R.sup.4 is straight or branched chain alkyl of 1 to 4 carbon atoms; andn is one of the integers 2, 3 or 4;or a pharmaceutically acceptable salt thereof, are Class I anti-arrhythmic agents useful in the treatment of cardiac arrhythmias and conditions characterized by coronary arteries vasospasm and myocardial ischemia.

Abstract: Disclosed herein is a process for producing an asymmetric indoline-2-carboxylic acid of the structural Formula: ##STR1## wherein X is hydrogen, bromine, chlorine, C.sub.1-4 alkyl or C.sub.1-4 alkoxy, which comprises:(a) assymetrically reducing an o-nitrophenylpyruvic acid III by contacting the acid III with a reducing complex formed from (R)-proline or (S)-proline, respectively, and sodium borohydride in an inert solvent to form, respectively, an (S) or (R)-.alpha.-hydroxy-2-nitrobenzenepropanoic acid IV;(b) reacting, respectively, said (S) or (R)-.alpha.-hydroxy-2-nitrobenzenepropanoic acid III with a Vilsmeier chlorinating reagent in which the chlorinating agent thereof is selected from a group consisting of thionyl chloride, oxalyl chloride, phosphorus oxychloride, phosphorus pentachloride and sulfuryl chloride and the amide thereof is selected from a group consisting of dimethylformamide, diethylformamide, dimethylacetamide and diethylacetamide, said reaction being run at temperatures of at least 20.

Abstract: This invention provides Class III anti-arrhythmic agents of the formula: ##STR1## in which R.sup.1 is alkylsulfonamido, arylsulfonamido, perfluoroalkylsulfonamido, R.sup.2 and R.sup.3 are hydrogen or alkyl, R.sup.4 is alkyl, and n is 2 to 4, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides a group of anti-arrhythmic agents of the formula: ##STR1## in which R.sup.1 is hydrogen, hydroxy, alkoxy or halo;R.sup.2 is hydrogen, alkoxy, halo or trifluoromethyl, with the proviso that R.sup.2 is not hydrogen when R.sup.1 is hydrogen;R.sup.3 is alkyl or, when R.sup.2 is trifluoromethyl and R.sup.1 is hydrogen, R.sup.3 may be hydrogen;R.sup.4 is alkyl, cycloalkyl or cycloalkylmethyl;R.sup.5 is hydrogen or alkyl;n is 2-4;or a pharmaceutically acceptable salt thereof.

Abstract: N-Aminoalkyl(aminophenyl)sulfonic acid amides of the formula: ##STR1## in which R.sup.1 is --NH.sub.2, alkylamino of 1 to 3 carbon atoms or alkanoylamino of 2 to 4 carbon atoms, in 3- or 4-position of the benzene ring;R.sup.2 is hydrogen or alkyl of 1 to 4 carbon atoms;R.sup.3 is hydrogen or straight or branched chain alkyl of 1 to 4 carbon atoms;R.sup.4 is straight or branched chain alkyl of 1 to 4 carbon atoms; with the proviso that R.sup.3 and R.sup.4 are branched chain alkyl when R.sup.2 is hydrogen;and n is one of the integers 2, 3 or 4;or a pharmaceutically acceptable salt thereof, an anti-arrhythmic agents useful in the treatment of cardiac arrhythmias and conditions characterized by coronary arteries vasospasm.

Abstract: Compounds presenting the following structural formula: ##STR1## in which the nitro substituent is in 3 or 4 position of the phenyl ring; R.sup.1 is hydrogen or alkyl;R.sup.2 is alkyl;R.sup.3 is hydrogen or alkyl;and n is one of the integers 0, 1 or 2;or a pharmaceutically acceptable salt thereof, are Class III anti-arrhythmic agents.

Abstract: Disclosed herein is a process for producing an asymmetric indoline-2-carboxylic acid of the structural Formula: ##STR1## wherein X is hydrogen, bromine, chlorine, C.sub.1-4 alkyl or C.sub.1-4 alkoxy, which comprises:(a) assymetrically reducing an o-nitrophenylpyruvic acid III by contacting the acid III with a reducing complex formed from (R)-proline or (S)-proline, respectively, and sodium borohydride in an inert solvent to form, respectively, an (S) or (R)-.alpha.-hydroxy-2-nitrobenzenepropanoic acid IV;(b) reacting, respectively, said (S) or (R)-.alpha.-hydroxy-2-nitrobenzenepropanoic acid III with a Vilsmeier chlorinating reagent in which the chlorinating agent thereof is selected from a group consisting of thionyl chloride, oxalyl chloride, phosphorus oxychloride, phosphorus pentachloride and sulfuryl chloride and the amide thereof is selected from a group consisting of dimethylformamide, diethylformamide, dimethylacetamide and diethylacetamide, said reaction being run at temperatures of at least 20.

Abstract: Compounds of the formula: ##STR1## in which Z is ##STR2## where R is hydrogen, alkyl, polyfluorinated alkyl, --CN, cyanoalkyl, cycloalkyl or cycloalkylalkyl;R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7, independently, are hydrogen, alkoxy, trifluoromethyl or halo;R.sup.8 is hydrogen or alkyl;or a pharmaceutically acceptable salt thereof, are useful as anti-arrhythmic agents.

Abstract: Disclosed herein is a process for producing an asymmetric indoline-2-carboxylic acid of the structural Formula: ##STR1## wherein X is hydrogen, bromine, chlorine, C.sub.1-4 alkyl or C.sub.1-4 alkoxy, which comprises:(a) assymetrically reducing an o-nitrophenylpyruvic acid III by contacting the acid III with a reducing complex formed from (R)-proline or (S)-proline, respectively, and sodium borohydride in an inert solvent to form, respectively, an (S) or (R)-.alpha.-hydroxy-2-nitrobenzenepropanoic acid IV;(b) reacting, respectively, said (S) or (R)-.alpha.-hydroxy-2-nitrobenzenepropanoic acid III with a Vilsmeier chlorinating reagent in which the chlorinating agent thereof is selected from a group consisting of thionyl chloride, oxalyl chloride, phosphorus oxychloride, phosphorus pentachloride and sulfuryl chloride and the amide thereof is selected from a group consisting of dimethylformamide, diethylformamide, dimethylacetamide and diethylacetamide, said reaction being run at temperatures of at least 20.

Abstract: An anti-arrhythmic agent which is N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-N-(1-methylethyl)- 2,3,4-trimethoxy-benzenesulfonamide or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein is a process for the preparation of optically active compounds of the formula: ##STR1## in which R is a lower alkyl, lower alkoxy, benzyloxy, phenyl, o-nitrophenyl, p-nitrophenyl, or p-tolyl group, or salts or esters thereof, which process comprises the following steps:(a) starting with a racemic mixture of the compound of Formula I in which R is phenyl, namely, (+)-3-benzoylthio-2-methylpropanoic acid;(b) adding thereto 0.40-0.

Abstract: Compounds of the formula: ##STR1## in which Y is --(CH.sub.2).sub.n -- where n is one of the integers 1,2,3 or 4 or ##STR2## where R is hydrogen, alkyl, polyfluorinated alkyl, --CN, cyanoalkyl, cycloalkyl or cycloalkylalkyl;R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7, independently, are hydrogen, alkoxy, trifluoromethyl or halo;R.sup.8 is hydrogen or alkyl;R.sup.9 is alkyl;R.sup.10 is alkyl;m is one of the integers 0 or 1;p is one of the integers 0, 1, 2 or 3; ands is one of the integers 0 or 1;or a pharmaceutically acceptable salt thereof, are useful as anti-arrhythmic agents.

Abstract: Described herein is a process for separating the enantiomers of (+)-2,3-dihydroindole-2-carboxylic acid, which process utilizes (+) or (-)-ephedrine as the resolving agent. The resolved acids are useful as intermediates in the preparation of angiotensin converting enzyme inhibitors.